Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys plans to aggressively expand Monjuvi, but has holes to fill in early stage pipeline

By stephen hansen, associate editor
September 16, 2020 11:39 PM UTC
Updated on Sep 18, 2020 at 7:53 PM UTC
Editor's note: This article has been updated to reflect the data on the FDA label for Monjuvi.

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the cash flows needed to rebuild MorphoSys’ early-stage pipeline. 

According to CEO Jean-Paul Kress, the near-term future and value of MorphoSys AG (Xetra:MOR; NASDAQ:MOR) are inextricably tied to the potential of Monjuvi tafasitimab-cxix in a range of hematologic cancers...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

MorphoSys AG